Literature DB >> 21808935

IAGG workshop: health promotion program on prevention of late onset dementia.

S Andrieu1, I Aboderin, J P Baeyens, J Beard, A Benetos, G Berrut, M Brainin, H B Cha, L K Chen, P Du, B Forette, F Forette, A Franco, L Fratiglioni, S Gillette-Guyonnet, G Gold, F Gomez, R Guimaraes, D Gustafson, A Khachaturian, J Luchsinger, F Mangialasche, H Mathiex-Fortunet, J P Michel, E Richard, L S Schneider, A Solomon, B Vellas.   

Abstract

IAGG, WHO, and SFGG organized a international workshop on Health promotion programs on prevention of late on-set dementia. Thirty world specialists coming from Europe, North America, Asia, South America, Africa and Australia, shared their experience on methods and results of large epidemiological interventions to reduce incidents of dementia or delay its on-set. Chaired by Laura FRATIGLIONI, an expert in Epidemiological studies on dementia issues, the workshop gave opportunity for discussions and controversies about the state-of-the-art. Based on different national and international trials (ADAPT, MAPT, FINGER, GUDIAGE, GEM etc) the questions remained opened for different aspects of methodology, the choice of domain or multi domain intervention, the choice and the definition of the target populations, the best age of candidates, the issues related to the discrepancy between late effects, and interventions' duration. We are please to publish in the Journal, the presentations presented to this workshop. These publications will complete previously task force published in the journal in the last two years on methodological issues for Alzheimer's trials including end point, biomarkers, and the experience of past therapeutic trials.

Entities:  

Mesh:

Year:  2011        PMID: 21808935     DOI: 10.1007/s12603-011-0142-1

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  6 in total

1.  Dose ranging for trials through biomarkers of drug effects.

Authors:  W Z Potter
Journal:  J Nutr Health Aging       Date:  2010-04       Impact factor: 4.075

2.  What we have learned from the Myriad trials.

Authors:  S B Hendrix; G K Wilcock
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

3.  What we have learned from the Xaliproden Sanofi-aventis trials.

Authors:  P Douillet; J M Orgogozo
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

4.  Study design considerations: conducting global clinical trials in early Alzheimer's disease.

Authors:  R J Schindler
Journal:  J Nutr Health Aging       Date:  2010-04       Impact factor: 4.075

5.  Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease.

Authors:  J M Cedarbaum; G Crans; M Grundman
Journal:  J Nutr Health Aging       Date:  2010-04       Impact factor: 4.075

Review 6.  The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).

Authors:  C C Gispen-de Wied; M Kritsidima; A J A Elferink
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

  6 in total
  11 in total

1.  Recruitment, retention and other methodological issues related to clinical trials for Alzheimer's disease.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

2.  Anthropometric measures and cognition in middle-aged HIV-infected and uninfected women. The Women's Interagency HIV Study.

Authors:  Deborah R Gustafson; Michelle M Mielke; Phyllis C Tien; Victor Valcour; Mardge Cohen; Kathryn Anastos; Chenglong Liu; Leigh Pearce; Elizabeth T Golub; Howard Minkoff; Howard A Crystal
Journal:  J Neurovirol       Date:  2013-12-12       Impact factor: 2.643

3.  Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.

Authors:  B Vellas; H Hampel; M E Rougé-Bugat; M Grundman; S Andrieu; S Abu-Shakra; R Bateman; R Berman; R Black; M Carrillo; M Donohue; M Mintun; J Morris; R Petersen; R G Thomas; J Suhy; L Schneider; L Seely; P Tariot; J Touchon; M Weiner; C Sampaio; P Aisen
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

4.  Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial).

Authors:  I Carrié; G Abellan van Kan; S Gillette-Guyonnet; S Andrieu; J-F Dartigues; J Touchon; T Dantoine; O Rouaud; M Bonnefoy; P Robert; M-N Cuffi; L Bories; S Bordes; Y Gasnier; F Desclaux; K Sudres; A Pesce; B Vellas
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

5.  Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.

Authors:  P A Dacks; D W Shineman; H M Fillit
Journal:  J Nutr Health Aging       Date:  2013-03       Impact factor: 4.075

6.  MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA.

Authors:  B Vellas; I Carrie; S Gillette-Guyonnet; J Touchon; T Dantoine; J F Dartigues; M N Cuffi; S Bordes; Y Gasnier; P Robert; L Bories; O Rouaud; F Desclaux; K Sudres; M Bonnefoy; A Pesce; C Dufouil; S Lehericy; M Chupin; J F Mangin; P Payoux; D Adel; P Legrand; D Catheline; C Kanony; M Zaim; L Molinier; N Costa; J Delrieu; T Voisin; C Faisant; F Lala; F Nourhashémi; Y Rolland; G Abellan Van Kan; C Dupuy; C Cantet; P Cestac; S Belleville; S Willis; M Cesari; M W Weiner; M E Soto; P J Ousset; S Andrieu
Journal:  J Prev Alzheimers Dis       Date:  2014-06

7.  Towards a comprehensive public health response to population ageing.

Authors:  John R Beard; David E Bloom
Journal:  Lancet       Date:  2014-11-06       Impact factor: 79.321

8.  Dementia prevention: current epidemiological evidence and future perspective.

Authors:  Francesca Mangialasche; Miia Kivipelto; Alina Solomon; Laura Fratiglioni
Journal:  Alzheimers Res Ther       Date:  2012-02-13       Impact factor: 6.982

9.  The recent decline in prevalence of dementia in developed countries: implications for prevention in the Republic of Korea.

Authors:  Yunhwan Lee
Journal:  J Korean Med Sci       Date:  2014-07-11       Impact factor: 2.153

10.  First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementia.

Authors:  Frank C Barone; Deborah Gustafson; Howard A Crystal; Herman Moreno; Mateusz G Adamski; Ken Arai; Alison E Baird; Clotilde Balucani; Adam M Brickman; David Cechetto; Philip Gorelick; Geert Jan Biessels; Amanda Kiliaan; Lenore Launer; Julie Schneider; Farzaneh A Sorond; Rachel Whitmer; Clinton Wright; Zheng Gang Zhang
Journal:  J Transl Med       Date:  2016-02-13       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.